Medtronic Lays Out Plans To Achieve 5%+ Annual Growth
The medtech giant offered additional details on its ongoing restructuring plan intended to make the company more competitive.
You may also be interested in...
The SMART trial will compare Medtronic’s Evolut TAVR systems to Edward’s Sapien 3 devices. Evolut EXPAND TAVR I will evaluate Evolut in patients with symptomatic moderate aortic stenosis or asymptomatic severe disease.
The deal gives Medtronic the exclusive right to acquire Half Moon Medical, a start-up developing a mitral valve repair system to compete with Abbott’s MitraClip.
Cue’s point-of-care molecular test earned an FDA emergency use authorization in June.